Patient baseline demographics and clinical characteristics
| Add-on (N=277) | Switch (N=276) | |
|---|---|---|
| Female, n (%) | 227 (81.9) | 217 (78.6) |
| White, n (%) | 258 (93.1) | 253 (91.7) |
| Age, mean (SD), years | 53.0 (13.4) | 53.6 (11.9) |
| Aged ≥65 years, n (%) | 53 (19.1) | 52 (18.8) |
| BMI, mean (SD), kg/m2 | 26.3 (5.2) | 26.5 (5.1) |
| Duration of RA, mean (SD), years | 8.2 (8.0) | 8.3 (8.4) |
| Categorical duration of RA in years, n (%) | ||
| <2 | 51 (18.4) | 66 (23.9) |
| 2 to <5 | 76 (27.4) | 68 (24.6) |
| 5 to <10 | 66 (23.8) | 63 (22.8) |
| ≥10 | 84 (30.3) | 79 (28.6) |
| SJC (66), mean (SD) | 14.4 (8.9) | 15.3 (10.2) |
| TJC (68), mean (SD) | 25.8 (13.9) | 26.6 (15.2) |
| DAS28-ESR, mean (SD) | 6.33 (0.98) | 6.36 (1.00) |
| HAQ-DI, mean (SD) | 1.46 (0.65) | 1.48 (0.60) |
| GSS,* mean (SD) | 36.9 (33.2) | 41.2 (40.0) |
| Annualised progression rate,* mean, units/year | 4.50 | 4.95 |
| MTX dose, mean (SD), mg/week | 16.2 (4.4) | 16.6 (4.9) |
| No. of previous csDMARDs (including MTX) prior to study entry, mean (SD) | 1.9 (1.1) | 1.9 (1.0) |
| Oral steroid use, n (%) | 140 (50.5) | 140 (50.7) |
| Oral steroid dose (prednisone equivalents), median, mg/day | 5.0 | 5.0 |
| Oral steroid dose (prednisone equivalents), mean (SD), mg/day | 6.88 (2.7) | 6.69 (2.5) |
*Campaign 2: X-ray assessments at baseline and week 104.
BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-ESR, Disease Activity Score in 28 joints using erythrocyte sedimentation rate; GSS, Genant-modified Sharp Score; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; RA, rheumatoid arthritis; SJC (66), swollen joint count using 66 joints; TJC (68), tender joint count using 68 joints.